IFRX News and Press, InflaRx N.V. From 11/02/23

InflaRx N.V. (IFRX) is expected to report $-0.29 for Q3 2023

2023-11-01 07:46:02 ET More on InflaRx InflaRx: Small German Company Targeting A Rare Indication EU regulators accept InflaRX vilobelimab application for review Seeking Alpha’s Quant Rating on InflaRx Historical earnings data for InflaRx Financ...

Single ascending dose (SAD) Phase I data confirm best-in-class potential of orally available C5aR inhibitor INF904; multiple ascending dose (MAD) part ongoing Six clinical sites initiated; first patients screened in Phase III trial of vilobelimab in pyoderma gangrenosum (PG) FDA r...

2023-09-06 17:31:58 ET Summary InflaRx is a developer of complement mediated therapies for inflammatory diseases. Their lead asset, vilobelimab, is a C5a inhibitor targeting Pyoderma Gangraenosum in a phase 3 trial. The company has a cash runway of 7-8 quarters and raised $40m...

2023-08-30 09:49:13 ET More on InflaRx InflaRx N.V.: Late Entrant Into The Covid Space InflaRx starts public offering of ordinary stock InflaRx stock surges as Staidson amends contract on COVID drug, $2.5M equity funding InflaRx seeks FDA emergency use nod fo...

MAA for vilobelimab was submitted in July MAA has been validated by EMA and is now under review Regulatory submission based on pivotal data from PANAMO Phase III trial Company announces attendance at upcoming scientific and investor events JENA, Germany, Aug. 30,...

2023-08-10 10:26:37 ET InflaRx press release ( NASDAQ: IFRX ): Q2 GAAP EPS of -€0.14. As of June 30, 2023, the Company’s total available funds were approximately €115.2 million, composed of €19.5 million in cash and cash equivalents and €...

• Quarter highlighted by the Emergency Use Authorization (EUA) and commercial launch of Gohibic (vilobelimab) in the United States • Oral C5aR inhibitor INF904 progressing in single ascending dose (SAD) and multiple ascending dose (MAD) Phase I trial •...

2023-07-10 17:27:14 ET Gainers: Chijet Motor Company ( NASDAQ: CJET ) +5% . InflaRx ( IFRX ) +5% . Avidity Biosciences ( RNA ) +4% . WD-40 Company ( WDFC ) +4% . Greenidge Generation Holdings  ( GREE ) +4% . Losers...

2023-06-28 07:50:53 ET clinical-stage biopharmaceutical company InflaRx N.V. ( NASDAQ: IFRX ) appoints Dr. Camilla Chong as Chief Medical Officer (CMO) of InflaRx, effective July 1, 2023. Dr. Chong is a medical doctor with extensive experience in the pharmac...